BIOCRYST PHARMACEUTICALS INC
No SEC Form 4 filings for $BCRX in the last 30 days.
BioCryst Pharmaceuticals said it will permanently close its Birmingham-area Discovery Center of Excellence and discontinue internal drug discovery. A WARN filing dated Aug. 4 shows layoffs of 47 employees at its Hoover facility starting Oct. 7. The company cut 2026 non-GAAP operating expense guidance to $420 million to $440 million and plans to keep advancing navenibart and BCX17725.
BioCryst Pharmaceuticals reported Q2 2026 results driven by ORLADEYO capsule demand, with total revenue up 45% YoY excluding divested European operations. Management said it ended internal drug discovery and closed its Birmingham unit. Full-year 2026 ORLADEYO guidance remains $625M to $645M. Cash and investments were over $350M.
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 BioCryst Reports Second Quarter 2026 Financial Results — Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 mil
Over the past 7 days, alphai's AI scored 3 news stories mentioning BCRX (BIOCRYST PHARMACEUTICALS INC). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent BCRX coverage spans financial news, corporate actions and earnings.
The WARN filing confirms workforce reduction timing and supports the company’s cost-cutting narrative tied to winding down internal discovery.
Guidance maintenance with operational pivot and pediatric launch momentum is likely supportive, but the biggest clinical catalysts are still dated (navenibart data in Q3 2027, BCX17725 proof-of-concept by end-2026).
Guidance raise plus ORLADEYO pediatric oral pellet shipments and completed navenibart enrollment are near-term catalysts for revenue trajectory and sentiment.
Executive CSO creation and leadership change signals renewed emphasis on rare disease R&D and partnership-driven pipeline build.
The new CSO role signals an organizational push to accelerate rare-disease pipeline development via external innovation, which can affect execution risk and near-term sentiment.
alphai scores every news story that mentions BCRX with an AI model for sentiment and relevance, and aggregates insider trades from BIOCRYST PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioCryst Pharmaceuticals said it will permanently close its Birmingham-area Discovery Center of Excellence and discontinue internal drug discovery. A WARN filing dated Aug. 4 shows layoffs of 47 employees at its Hoover facility starting Oct. 7. The company cut 2026 non-GAAP operating expense guidance to $420 million to $440 million and plans to keep advancing navenibart and BCX17725.
4 min readBioCryst Pharmaceuticals reported Q2 2026 results driven by ORLADEYO capsule demand, with total revenue up 45% YoY excluding divested European operations. Management said it ended internal drug discovery and closed its Birmingham unit. Full-year 2026 ORLADEYO guidance remains $625M to $645M. Cash and investments were over $350M.
6 min readBIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 BioCryst Reports Second Quarter 2026 Financial Results — Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 mil
6 min readBioCryst Pharmaceuticals (Nasdaq: BCRX) appointed David W. Jenkins as Chief Scientific Officer, effective immediately, to lead research and external innovation for rare disease therapies. The company cited its ORLADEYO success and reported Q1 2026 net revenue of $148.3M, up 11% YoY. BioCryst had $260.8M cash, rising to $330.8M pro forma after $70M upfront from a European Navenibart deal.
3 min readBioCryst Pharmaceuticals (Nasdaq: BCRX) appointed David W. Jenkins as Chief Scientific Officer, effective immediately, reporting to Chief R&D Officer Sandeep Menon. Jenkins previously led external innovation at Ipsen and oversaw adding 35+ assets to its pipeline. The role focuses on using partnerships to accelerate rare-disease therapies. BioCryst also cites ORLADEYO (berotralstat) commercialization.
3 min readBiotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).
7 min readBioCryst Pharmaceuticals (Nasdaq: BCRX) said its board compensation committee granted inducement equity to nine newly hired employees: stock options for 33,950 shares and RSUs for 91,750 shares, effective July 1, 2026, under Nasdaq Rule 5635(c)(4). Options exercise price is $9.65 (grant-date close); both vest annually over four years.
2 min readA roundup of analysts’ June 30 price-target changes across many stocks. Examples: Wells Fargo raised AAL to $17 from $12; Leerink raised ABVX to $148 from $140; JPMorgan cut ACI to $20 from $22; Jefferies cut ALB to $211 from $244; Goldman cut APA to $32 from $34; KeyCorp raised ATI to $211 from $175.
2 min readBIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1 BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED AS OF APRIL 20, 2026) ARTICLE One GENERAL PROVISIONS I. PURPOSES OF THE PLAN A. This Stock Incentive Plan (the “Plan”), formerly the “BioCryst Pharmaceutic
2 min readBioCryst said it expects ORLADEYO to reach $1B peak sales, citing payer mix of ~60% commercial, 20% Medicare Part D and 20% Medicaid and gross-to-net around 15% last year. Pediatric ORLADEYO launch was delayed by a batch manufacturing issue, not safety-related. In Phase 3, navenibart ALPHA-ORBIT enrollment should finish by end-June; top-line data due Q3 next year, with a likely 2H 2028 launch. BioCryst reported pro forma cash of $330M and expects profitability this year and next.
6 min read
